Axogen Inc. logo

Axogen Inc. (0HKD)

Market Closed
8 Dec, 15:30
LSE LSE
$
31. 71
-1.87
-5.57%
$
- Market Cap
- P/E Ratio
4% Div Yield
2,622 Volume
-0.19 Eps
$ 33.58
Previous Close
Day Range
31.66 33.32
Year Range
3.5 33.32
Want to track 0HKD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 77 days

Summary

0HKD closed today lower at $31.71, a decrease of 5.57% from yesterday's close, completing a monthly increase of 7.49% or $2.21. Over the past 12 months, 0HKD stock gained 87.08%.
0HKD pays dividends to its shareholders, with the most recent payment made on Feb 12, 2010. The next estimated payment will be in 12 Feb 2011 on Feb 12, 2011 for a total of $1.
The last earnings report, released on Nov 05, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 23, 2026.
Axogen Inc. has completed 3 stock splits, with the recent split occurring on Jul 11, 1994.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).

0HKD Chart

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on Avance Nerve Graft, a pivotal regulatory inflection point. The BLA submission features over a decade of real-world outcomes, robust manufacturing validation, and clinical recovery rates in the low-80% range.

Seekingalpha | 6 days ago
AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates

AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Zacks | 1 month ago
Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know

Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 76.4% in AxoGen (AXGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 3 months ago

Axogen Inc. (0HKD) FAQ

What is the stock price today?

The current price is $31.71.

On which exchange is it traded?

Axogen Inc. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is 0HKD.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Feb 23, 2026.

Has Axogen Inc. ever had a stock split?

Axogen Inc. had 3 splits and the recent split was on Jul 11, 1994.

Axogen Inc. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Michael D. Dale CEO
LSE Exchange
US05463X1063 ISIN
US Country
451 Employees
12 Feb 2010 Last Dividend
11 Jul 1994 Last Split
27 Mar 1990 IPO Date

Overview

AxoGen, Inc., alongside its subsidiaries, plays a pivotal role in advancing the field of peripheral nerve regeneration and repair around the globe. This innovative company is focused on developing and bringing to market specialized technologies that address critical needs in nerve repair. By providing state-of-the-art solutions, AxoGen, Inc. is committed to improving the quality of life for patients suffering from peripheral nerve injuries. The company serves a diverse clientele, including hospitals, surgery centers, military hospitals, as well as plastic reconstructive, orthopedic, and hand surgeons, and oral and maxillofacial surgeons, operating out of its headquarters in Alachua, Florida.

Products and Services

  • Avance Nerve Graft

    A pioneering product in nerve repair, the Avance Nerve Graft is a biologically active, off-the-shelf processed human nerve allograft designed for bridging severed peripheral nerves. This innovative solution offers a significant advantage by eliminating the comorbidities associated with harvesting grafts from a second surgical site, thereby facilitating a more efficient and less invasive recovery for patients.

  • AxoGuard Nerve Connector

    This product takes advantage of a porcine submucosa extracellular matrix (ECM) to assist in the tensionless repair of severed peripheral nerves. The AxoGuard Nerve Connector facilitates the precise alignment and connection of nerve endings, promoting optimal healing and nerve function recovery.

  • AxoGuard Nerve Protector

    As a porcine submucosa ECM product, the AxoGuard Nerve Protector is utilized to wrap and safeguard damaged peripheral nerves. It plays a vital role in nerve reconstruction by reinforcing the repair process while preventing soft tissue attachments, thereby ensuring the integrity and functionality of the nerve post-repair.

  • Axoguard HA+ Nerve Protector

    This advanced version incorporates a processed porcine submucosa ECM base layer along with a hyaluronate-alginate gel coating. The Axoguard HA+ Nerve Protector is specifically designed to provide both short and long-term protection for peripheral nerve injuries, offering an enhanced barrier and healing environment.

  • Axoguard Nerve Cap

    The Axoguard Nerve Cap is crafted from a porcine submucosa ECM and is used to protect the end of a peripheral nerve. It effectively isolates the nerve from the surrounding tissues to minimize the development of symptomatic or painful neuroma, thereby contributing to a better patient outcome.

  • AxoTouch Two-Point Discriminator

    This specialized tool is employed for measuring the innervation density of the skin's surface area. The AxoTouch Two-Point Discriminator is an essential instrument for assessing the success of nerve repair and recovery, providing valuable feedback for surgeons and patients alike.

Contact Information

Address: 13631 Progress Boulevard
Phone: 386 462 6800